DBS treatment may slow the progression of Parkinson's tremor in early-stage patients

June 29, 2018, Vanderbilt University Medical Center
Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia

Deep brain stimulation (DBS) may slow the progression of tremor for early-stage Parkinson's disease patients, according to a Vanderbilt University Medical Center study released in the June 29 online issue of Neurology, the medical journal of the American Academy of Neurology.

The study is the first evidence of a treatment that slows the progression of one of the cardinal features of Parkinson's, but a larger-scale clinical trial across multiple investigational centers is needed to confirm the finding.

"The finding concerning tremor progression is truly exceptional," said senior author David Charles, MD, professor and vice-chairman of Neurology. "It suggests that DBS applied in early-stage Parkinson's may slow the progression of tremor, which is remarkable because there are no treatments for Parkinson's that have been proven to slow the progression of any element of the disease."

Patients in the Vanderbilt study were randomized to receive DBS plus drug therapy or drug therapy alone; the drug therapy alone group was seven times more likely to develop new rest tremor after two years in comparison to the DBS plus drug therapy group.

The trial, which began in 2006, was controversial because it recruited with early-stage Parkinson's disease for DBS brain surgery. At that time, DBS was approved for only advanced-stage Parkinson's disease when symptoms were no longer adequately controlled by medication.

"Since this was the first early DBS trial, it was unknown whether there were individual motor symptoms very early in Parkinson's disease that may be more potently improved by DBS," said lead author Mallory Hacker, Ph.D., research assistant professor of Neurology.

The post hoc analysis showed that 86 percent of the therapy patients developed rest tremor in previously unaffected limbs over the course of the two-year period, while that occurred in only 46 percent of patients who had received DBS therapy in addition to . Four of the DBS patients had rest tremor improvement and rest tremor completely disappeared from all affected limbs for one DBS patient.

The FDA has approved Vanderbilt to lead a large-scale, Phase III multicenter study that will enroll 280 people with very early-stage Parkinson's disease, beginning in 2019, and 17 other U.S. medical centers have joined the DBS in Early Stage Parkinson's Disease Study Group to participate.

"The field of DBS for Parkinson's disease is moving toward earlier stages of treatment, therefore, we must conduct the pivotal trial to ensure patient safety and provide the Parkinson's community with the best possible medical evidence to guide treatment," Charles said.

Explore further: FDA approves brain stimulation device for Parkinson's disease

Related Stories

FDA approves brain stimulation device for Parkinson's disease

June 14, 2015
(HealthDay)—The U.S. Food and Drug Administration on Friday approved a device that can be implanted into the brain to help people battling Parkinson's disease.

Focused ultrasound for treating Parkinson's disease to be tested

October 12, 2012
(Medical Xpress)—After a promising clinical trial of focused ultrasound as a potential treatment for essential tremor, the University of Virginia Health System is launching a new study to investigate the scalpel-free technology's ...

Cognitive stress reduces levodopa effect in Parkinson's

January 13, 2017
(HealthDay)—Cognitive co-activation is associated with a significantly smaller levodopa effect on resting tremor in Parkinson's disease (PD), according to a study published online Jan. 10 in CNS Neuroscience & Therapeutics.

Finding a treatment for Parkinson's disease dementia

September 2, 2015
University of Adelaide neuroscientists are leading a world-first study into a form of dementia experienced by many Parkinson's disease suffers, which is expected to ultimately lead to a new therapy for the condition.

Recommended for you

Researchers trace Parkinson's damage in the heart

July 13, 2018
A new way to examine stress and inflammation in the heart will help Parkinson's researchers test new therapies and explore an unappreciated way the disease puts people at risk of falls and hospitalization.

Study raises doubts on a previous theory of Parkinson's disease

July 6, 2018
Parkinson's disease was first described by a British doctor more than 200 years ago. The exact causes of this neurodegenerative disease are still unknown. In a study recently published in eLife, a team of researchers led ...

Drug protects neurons in Parkinson's disease

June 27, 2018
Systemic treatment of animal models with israpidine, a calcium channel inhibitor, reduced mitochondrial stress that might cause Parkinson's disease, according to a Northwestern Medicine study published in the Journal of Clinical ...

Half of those on Parkinson's drugs may develop impulse control problems

June 20, 2018
Over time, half of the people taking certain drugs for Parkinson's disease may develop impulse control disorders such as compulsive gambling, shopping or eating, according to a study published in the June 20, 2018, online ...

New evidence sheds light on how Parkinson's disease may happen

June 14, 2018
Researchers at Baylor College of Medicine and Texas Children's Hospital have identified unexpected new key players in the development of an early onset form of Parkinson's disease called Parkinsonism. These key players are ...

Scientists unravel molecular mechanisms of Parkinson's disease

June 12, 2018
Detailed brain cell analysis has helped researchers uncover new mechanisms thought to underlie Parkinson's disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.